most popular glp-1 drugs America's Poison Centers GLP-1 Market Industry Trends and

Carey MD Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore

Incretin based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes

The lead study author and doctors share how these unknown side effects can impact your training and the best ways to adjust your workout routine when taking a GLP-1.

Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection